✦ LIBER ✦

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

✍ Scribed by Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Tubiana-Mathieu, Nicole; Cany, Laurent; Catala, Stéphanie; Khayat, David; Pauporté, Iris; Kramar, Andrew

Book ID: 120531275
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 358 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70225-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PERSEPHONE is a randomised phase III con

PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer

✍ Earl, Helena; Cameron, David; Miles, David; Wardley, Andrew; Ogburn, Emma; Valli 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

✍ José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambu 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 320 KB

Adjuvant lapatinib for women with early-

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

✍ Paul E Goss; Ian E Smith; Joyce O'Shaughnessy; Bent Ejlertsen; Manfred Kaufmann; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 315 KB

Multicentric, Randomized Phase III Trial

Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)

✍ Valentina Guarneri; Antonio Frassoldati; Paolo Bruzzi; Roberto D'Amico; Maurizio 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 95 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

## Background: Patients with progressive disease after two or more her2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. we aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent dm1 linked to trastuzumab,